Ubiquitin Carboxyl Terminal Hydrolase L1 (UCHL1) Antibody

Documentos del producto

Especificaciones del producto

Primary Antibodies

Target: Ubiquitin Carboxyl Terminal Hydrolase L1 (UCHL1)
Immunogen: abx069586 - Recombinant UCHL1 (Gln2-Ala223) expressed in E. coli

Rabbit

Mouse

WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC (Predicted): 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.

Polyclonal

Unconjugated

Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography.

100 µl

200 µl

1 ml

Liquid

WB, IHC, FCM

0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.

Shipped within 5-7 working days.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

Q9R0P9

HEL-117,HEL-S-53,NDGOA,PARK5 PGP 9.5,PGP9.5,PGP95,SPG79,SPG79A,UCHL-1 Uch-L1,Neuron cytoplasmic protein 9.5,Ubiquitin thioesterase L1

Antibody anti-UCHL1

RUO

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Background

UCHL1 is a deubiquitinating enzyme that cleaves ubiquitin from protein substrates, playing a pivotal role in the ubiquitin-proteasome system (UPS). UCHL1 is highly expressed in neurons and is crucial for maintaining protein homeostasis, axonal transport, and synaptic function. It regulates the degradation of misfolded proteins, ensuring neuronal survival and preventing neurotoxicity. Mutations in UCHL1 are linked to neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease due to impaired protein turnover and accumulation of toxic aggregates. It also has oncogenic and tumor-suppressive roles depending on the cellular context, regulating cell cycle progression and apoptosis. Knockout studies in mice show progressive neurodegeneration, motor dysfunction, and impaired synaptic activity, highlighting UCHL1’s critical role in neuronal maintenance, proteostasis, and neuroprotection.